Alto Neuroscience, Inc. Total Liabilities
Alto Neuroscience, Inc. total liabilities. Based on the latest financial reports, Alto Neuroscience, Inc. (ANRO) has total liabilities worth $33.55 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ANRO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Alto Neuroscience, Inc. (2021–2025)
Total liabilities of Alto Neuroscience, Inc. from 2021 to 2025. This chart illustrates how Alto Neuroscience, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Alto Neuroscience, Inc. Competitors by Total Liabilities
The table below lists competitors of Alto Neuroscience, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangzhou Pearl River Piano Group Co Ltd
SHE:002678
|
China | CN¥594.22 Million |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥397.56 Million |
|
Dharma Satya Nusantara Ptdsn
JK:DSNG
|
Indonesia | Rp5.68 Trillion |
|
AIC Inc
TWO:3693
|
Taiwan | NT$2.52 Billion |
|
Zbit Semiconductor Inc. A
SHG:688416
|
China | CN¥101.00 Million |
|
Beijing Watertek Information Technology Co Ltd
SHE:300324
|
China | CN¥2.68 Billion |
|
Dashang Co Ltd
SHG:600694
|
China | CN¥7.82 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down Alto Neuroscience, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Alto Neuroscience, Inc. asset portfolio.
Liquidity & Leverage Metrics
Alto Neuroscience, Inc. Total Liabilities Ratios Explained
Alto Neuroscience, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alto Neuroscience, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alto Neuroscience, Inc. (2021–2025)
The table below shows the annual total liabilities of Alto Neuroscience, Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $33.55 Million | +28.62% |
| 2024-09-30 | $26.08 Million | -83.52% |
| 2023-09-30 | $158.30 Million | +77.35% |
| 2022-09-30 | $89.26 Million | +116.27% |
| 2021-09-30 | $41.27 Million | -- |
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clini… Read more